Merck drops two unpromising COVID-19 vaccines

Merck drops 2 unpromising COVID-19 vaccines
CBSNews
© Bloomberg
A Merck logo is pictured outside the entrance to a facility
Merck is pulling the plugs on two potential COVID-19 vaccines following poor results in early-stage studies. The drugmaker said Monday it will focus instead on studying two possible treatments for the virus that also have yet to be approved by regulators. 
Merck said its potential vaccines were well tolerated by patients, but they generated an inferior immune system response compared with other competitors' new vaccines. The company is focusing its efforts instead on advancing clinical programs and manufacturing for two potential treatment medications for the virus: MK-7110 and MK-4482 (also known as molnupiravir. Molnupiravir is being developed in collaboration with Ridgeback Bio.

Related Keywords

Kenilworth ,New Jersey ,United States ,Ridgeback Bio ,Hayley Mason ,Bloomberga Merck ,Richard Plemper ,Centers For Disease ,Pfizer ,Merck Research Laboratories ,Drug Administration ,Georgia State University ,Disease Control ,Operation Warp Speed ,கெநில்‌வர்த் ,புதியது ஜெர்சி ,ஒன்றுபட்டது மாநிலங்களில் ,ரிட்ஜ்பேக் உயிர் ,ஹேலி கொத்தனார் ,மையங்கள் க்கு நோய் ,ஃபைசர் ,மெர்க் ஆராய்ச்சி ஆய்வகங்கள் ,ஜார்ஜியா நிலை பல்கலைக்கழகம் ,நோய் கட்டுப்பாடு ,செயல்பாடு போரிடு வேகம் ,